The
Depolarization-induced Ca 2ϩ entry through voltage-gated Ca 2ϩ channels controls a number of important physiological properties, including muscle contraction, cardiac pacemaking, hormone secretion, neurotransmitter release, and neuronal plasticity. Several subfamilies of voltage-gated Ca 2ϩ channels with different pharmacological and biophysical properties evolved to serve these different physiological functions. Of these, the family of L-type Ca 2ϩ channels (LTCCs) is characterized by high sensitivity to organic Ca 2ϩ channel blockers (Catterall et al., 2005) . Four LTCC isoforms exist, containing either Ca v 1.1, Ca v 1.2, Ca v 1.3, or Ca v 1.4 pore-forming ␣ 1 subunits (Catterall et al., 2005) . Ca v 1.2 and Ca v 1.3 LTCCs display very similar pharmacological properties, and they exhibit an overlapping expression pattern in the cardiovascular system, endocrine cells (e.g., pancreatic ␤-cells), and neurons (Hell et al., 1993; SinneggerBrauns et al., 2004) . This has impeded distinction of their respective physiological roles. We have recently generated suitable mouse models to distinguish their contribution to different physiological processes. Whereas Ca v 1.2 channels regulate vascular tone and cardiac inotropy, Ca v 1.3 channels are crucial for pacemaking in sinoatrial node cells and atrioventricular conduction (Platzer et al., 2000; SinneggerBrauns et al., 2004) . In mice, fast insulin secretion is closely coupled to Ca v 1.2 function (Schulla et al., 2003; SinneggerBrauns et al., 2004) , whereas inner hair cell signaling and hearing depend on Ca v 1.3 (Platzer et al., 2000) .
The central nervous system employs Ca v 1.2 channels for late-phase long-term potentiation in hippocampal neurons and for spatial memory (Moosmang et al., 2005) , whereas Ca v 1.3 channels, which can activate at more negative voltages (Platzer et al., 2000; Koschak et al., 2001; Lipscombe et al., 2004) , seem to serve predominantly as modulators of neuronal spiking behavior and pacemaking (Olson et al., 2005; Chan et al., 2007) .
Ca v 1.3-deficient mice lack amphetamine-sensitized locomotor activity (Giordano et al., 2006) and exhibit an antidepressant-like phenotype . Ca v 1.3 channels may also play an important pathophysiological role in Parkinson disease (Chan et al., 2007) . Because presently available potent Ca 2ϩ channel blockers such as the 1,4-dihydropyridines (DHPs) inhibit both Ca v 1.2 and Ca v 1.3 (Koschak et al., 2001; Helton et al., 2005) , development of selective modulators of Ca v 1.3 channels would be required to determine whether they represent suitable targets to treat Parkinson disease, depression, and drug abuse. At present, it is unclear whether the highly conserved drug binding pockets (such as for the DHPs) of Ca v 1.2 and Ca v 1.3 channels offer enough structural heterogeneity to be exploited for that purpose. It also is still unresolved to what extent other LTCC isoforms (Ca v 1.1 and Ca v 1.4) can contribute to high-affinity drug binding in the central nervous system (Takahashi et al., 2003; Hemara-Wahanui et al., 2005) and could thus mediate pharmacological effects. These considerations raise two questions: 1) What are the expression levels of other LTCC isoforms (Ca v 1.1 and Ca v 1.4) in brain? 2) Does structural heterogeneity between the DHP binding pockets of Ca v 1.2 and Ca v 1.3 channels result in affinity differences that could be exploited for the development of isoform-selective modulators? This also raises a methodological issue, because although Ca v 1.3 channel complexes can be expressed for pharmacological analysis in mammalian cells, a native source of Ca v 1.3 channels is needed to validate data obtained with recombinant channels.
We employed a biochemical approach to address these questions, using a novel double-mutant mouse generated from previously established mouse models, radioligand binding assays, and extensive qPCR experiments.
Materials and Methods
Animals. The generation and detailed characterization of Ca v 1.2DHP(Ϫ/Ϫ) and Ca v 1.3(Ϫ/Ϫ) mice has been reported previously (Platzer et al., 2000; Sinnegger-Brauns et al., 2004) . Double mutant Ca v 1.2DHP(Ϫ/Ϫ) ϫ Ca v 1.3(Ϫ/Ϫ) mice were generated by crossing Ca v 1.3(Ϫ/Ϫ) male mice with Ca v 1.2DHP(Ϫ/Ϫ) female mice previously backcrossed into C57BL/6N background in five generations. Animals heterozygous for both mutant alleles were then crossed to obtain homozygous double mutants (referred to as Ca v -DM). Tissues and RNA from 3-to 16-month old male mice or 3-to 12-month old male Sprague-Dawley rats were used for experiments. Animal handling was approved by the Bundesministerium fü r Bildung, Wissenschaft und Kultur (Vienna, Austria) in accordance with international laws and policies of animal welfare.
Recombinant ␣ 1 cDNAs. The following ␣ 1 subunit cDNAs were used (GenBank accession numbers given in parentheses): rabbit Ca v 1.2 (X15539), human Ca v 1.3 (EU63339; Koschak et al., 2001) , and human Ca v 1.4 (variant of NM_005183; Koschak et al., 2003) . Replacement of phenylalanine by tyrosine at position 1414 in the Ca v 1.4 ␣ 1 subunit (numbering according to Koschak et al., 2003) to yield Ca v 1.4 F1414Y followed published PCR procedures , using an AgeI/EcoRI cassette. The mutation was confirmed by DNA sequencing (MWG Biotech, Ebersberg, Germany).
Transfection and Cell Culture. tsA201 cells were maintained in DMEM/F-12 medium (Invitrogen, Carlsbad, CA) enriched with 10% (v/v) fetal calf serum (SEBAK, Suben, Austria) and 2 mM L-glutamine and containing 44 mM NaHCO 3 . Cells were incubated at 5% CO 2 /37°C, plated on 10-cm culture dishes, and grown to approximately 70% confluence for transfection. ␣ 1 subunits were transiently expressed together with ␣ 2 ␦ 1 (Genbank accession number NM_001082276) and ␤ 1a (M25817) subunits in pcDNA3 (Invitrogen). Expression plasmids were combined at equimolar concentrations with a total subunit cDNA amount of 10.5 g per 10-cm culture dish. Cells were transfected by calcium phosphate precipitation of DNA according to standard protocols. Medium was refreshed 8 to 12 h after transfection. Cells were harvested after two more days of incubation.
Membrane Preparation and Immunoblot Analysis. Microsomal membranes from brain tissue and tsA201 cells were prepared as described previously (Glossmann and Ferry, 1985; Reimer et al., 2000; Sinnegger-Brauns et al., 2004) . Membrane protein concentrations were determined by Lowry or Bradford assays (Lowry et al., 1951; Bradford, 1976) with bovine serum albumin as a standard. Expression of recombinant proteins was monitored using Western Blot analysis as described previously .
Radioreceptor Assay. (ϩ)-[ 3 H]Isradipine (75-80 Ci/mmol) was purchased from PerkinElmer Life and Analytical Sciences (Vienna, Austria). Unlabeled racemic isradipine and (Ϫ)-isradipine were a gift from Novartis (Basel, Switzerland). (ϩ)-Tetrandrine was a gift from MSD Sharp and Dohme (Rahway, NJ). (ϩ)-cis-Diltiazem was from Gödecke (Freiburg, Germany). Mibefradil was provided by Roche (Basel, Switzerland). Azidopine was purchased from GE Healthcare (Chalfont St. Giles, Buckinghamshire, UK). Racemic nitrendipine and amlodipine as well as nifedipine were purchased from SigmaAldrich (Vienna, Austria). Stock solutions of all unlabeled drugs were prepared in dimethyl sulfoxide. Binding experiments were performed in binding buffer (50 mM Tris-HCl, pH 7.4, 0.1 mM phenylmethylsulfonyl fluoride, and 1 mM CaCl 2 ) in a final assay volume of 0.5 (brain microsomes) or 1 ml (tsA201 cell microsomes), respectively. Nonspecific binding was determined in the presence of 1 M unlabeled isradipine. After incubation for 90 to 120 min at 22°C or 60 min at 37°C (binding stimulation) in a water bath, free ligand was removed by rapid filtration of the assay mixture over GF/C Whatman glass fiber filters (Sigma-Aldrich, Vienna, Austria), which had been pretreated with 0.25% (v/v) polyethylenimine for 30 min at 22°C. Filters were washed three times with ice-cold buffer (50 mM TrisHCl, pH 7.4) and then counted for radioactivity to quantify bound ligand.
RNA Isolation and Reverse Transcription. Animals were euthanized by CO 2 exposure, and brains were excised after decapitation. Brain regions were dissected on ice with the help of a stereotaxic atlas (Franklin and Paxinos, 1997) . Tissue was shock-frozen in liquid nitrogen and stored at Ϫ80 C until further processing. Total RNA was isolated using the RNAqueous-4PCR Kit (Ambion, Austin, TX; for brain tissues) or the E.Z.N.A. Total RNA Kit (Omega Bio-tek, Doraville, GA; for skeletal muscle and eye) according to the manufacturers' instructions. Total RNA was treated with DNase I (RNAqueous-4PCR Kit; Ambion), which effectively removed genomic contamination. RNA integrity was routinely checked for the presence of distinct 28S and 18S rRNA bands after loading 1 to 2 g of RNA on a denaturating gel (formaldehyde SeaKem agarose gel, 1%). Total RNA (1 g) was reverse-transcribed using RevertAid H Minus first-strand cDNA Synthesis Kit with random hexamer primers (MBI Fermentas, St. Leon-Rot, Germany). RNA and cDNA concentrations were determined photometrically.
Quantitative Real-Time PCR. The relative abundance of different LTCC transcripts was assessed by TaqMan quantitative PCR using a standard curve method as described previously (Koschak et al., 2007) . Specific TaqMan Gene Expression Assays, designed to span exon-exon boundaries, were purchased from Applied Biosystems (Foster City, CA). The following primers (MWG Biotech) were used for PCR amplification of assay-specific fragments using whole brain cDNA as a template. Mouse: Ca v 1.1: forward, 5Ј-GTTACAT-GAGCTGGATCACACAG-3Ј; reverse, 5Ј-ATGAGCATTTCGATGGT-GAAG-3Ј. Ca V 1.2: forward, 5Ј-CATCACCAACTTCGACAACTTC-3Ј; reverse, 5Ј-CAGGTAGCCTTTGAGATCTTCTTC-3Ј. Ca V 1.3: forward, 5Ј-ACATTCTGAACATGGTCTTCACAG-3Ј; reverse, 5Ј-AGGACTTGA-TGAAGGTCCACAG-3Ј. Ca V 1.4: forward, 5Ј-CTCTTCATCTGTGGCA-ACTACATC-3Ј; reverse, 5Ј-GTACCACCTTCTCCTTGGGTACTA. Rat: Ca v 1.1: forward, 5Ј-CACACAGGGTAGCATGTAAGAGG-3Ј; reverse, 5Ј-TCGATACCCATAATATTCCTCCTG-3Ј. Ca v 1.2: forward, 5Ј-AAGA-CATAGACCCTGAGAATGAGG-3Ј; reverse, 5Ј-GAAGATCACCAGCC-AGTAGAAGAC-3Ј. Ca v 1.3: forward, 5Ј-ATTAGGTCTGAGTCAGGA-GACGAG-3Ј; reverse, 5Ј-TCGTCATCTTCTAAGAAACCTTGG-3Ј. Ca v 1.4: forward, 5Ј-TTCTACAGTTGCACTGATGAAGC-3Ј; reverse, 5Ј-AAGGCGATGATGATGATGTAGAC-3Ј. The integrity of the obtained fragments was confirmed by sequencing (MWG Biotech). Fragment concentrations were determined in a Wallac 1420 Multilabel Counter (PerkinElmer Life and Analytical Sciences) using the Quant-IT PicoGreen dsDNA Reagent (Invitrogen) according to the manufacturer's instructions, and standard curve dilutions were calculated subsequently. Four to five standard curves with 10-fold serial dilutions from 10 7 to 10 molecules of the respective fragment were generated for each assay. Assay efficiencies were calculated from the slope of the resulting average standard curve equation. Limits of quantification in the linear range of the individual standard curves were determined by calculating the relative S.D. of the replicate values obtained for each amount of fragment. The reliable quantification range was then defined by the fragment quanta at which measurements showed relative S.D. values of less than 1%. Assay IDs, their efficiency (E), and reliable quantification range (molecules) were as follows: Mouse: Ca v 1.1 ␣ 1 , Mm00489257_m1, E ϭ 94.9%, 10 3 to 10 7 ; Ca v 1.2 ␣ 1 , Mm00437917_m1, E ϭ 93.4%, 10 2 to 10 7 ; Ca v 1.3 ␣ 1 , Mm01209919_m1, E ϭ 97.0%, 10 2 to 10 7 ; Ca v 1.4 ␣ 1 , Mm00490443_m1, E ϭ 94.3%, 10 1 to 10 7 . Rat: Ca v 1.1 ␣ 1 , customized (target base 2302 according to GenBank accession number L04684), E ϭ 95.8%, 3 ϫ 10 2 to 2 ϫ 10 6 ; Ca v 1.2 ␣ 1 , Rn00709287_m1, E ϭ 95.6%, 10 2 to 10 7 ; Ca v 1.3 ␣ 1 , Rn01453378_m1, E ϭ 90.1%, 3 ϫ 10 2 to 10 7 ; Ca v 1.4 ␣ 1 , Rn00586734_m1, E ϭ 98.1%, 10 2 to 7 ϫ 10 6 . qPCR was performed in triplicate measurements using 20 ng of total RNA equivalents of cDNA and the specific TaqMan Gene Expression Assay in a final volume of 20 l in TaqMan Universal PCR Master Mix (Applied Biosystems). Samples were obtained from at least two independent reverse transcriptions of at least two independent RNA preparations from each species and strain examined (with the exception of muscle and eye controls, where only one reverse transcription of the respective preparations was performed). ␤-Actin transcript monitoring served to control the quality of RNA preparations and reverse transcriptions (mouse, Mm00607939_s1; rat, Rn01412977_g1). Samples containing RNA and samples without templates served as negative controls. Analysis was performed using the ABI PRISM 7500 Sequence Detector (Applied Biosystems). The relative abundance of each of the four different LTCC RNAs was expressed as the percentage of the sum of LTCC molecules per experiment.
Data Analysis and Statistics. Data were analyzed using Origin 6.1 (OriginLab Corp., Northampton, MA) and Prism 4.03 (GraphPad, San Diego, CA) employing the statistical tests indicated in the text and figure legends. P values Ͻ0.05 were considered statistically significant. Data are expressed as means Ϯ S.E.M.-except where indicated otherwise-for the given number of experiments. ]isradipine binding activity to 15% of wild-type (WT) levels in brain (Sinnegger-Brauns et al., 2004 (Platzer et al., 2000) . As a consequence, any residual binding in these mice should prompt a further biochemical analysis to determine a possible expression of other LTCCs. As expected, homozygous Ca v -DM mice were viable and their phenotype was indistinguishable from that of Ca v 1.3(Ϫ/Ϫ) mice (Platzer et al., 2000) .
Results

Residual LTCC Binding Activity in
In whole-brain microsomal membranes of Ca v 1.2DHP(Ϫ/Ϫ) mice, specific binding of the LTCC-selective high affinity probe (Fig. 1A) . A significant further reduction to 4.4 Ϯ 0.5% (p ϭ 0.0006, unpaired t test, n ϭ 5) of WT values was observed in Ca v -DM mice. Depending on experimental conditions [membrane protein concentration, presence of (ϩ)-cis-diltiazem, see Fig. 1 and Table 1 ], this residual specific binding corresponded to 100 to 700 dpm and was reproducible in three individual preparations. These data demonstrate that more than 95% of LTCC-associated DHP binding in mouse brain occurs at Ca v 1.2 and Ca v 1.3, the latter participating in 10.7% of (ϩ)-[ 3 H]isradipine binding activity. To determine whether the remaining activity is linked to LTCCs or represents specific binding to other proteins, we further examined its properties. A hallmark of DHP interaction with LTCC ␣ 1 -subunits is the specific stimulation by the structurally unrelated benzothiazepine (ϩ)-cis-diltiazem through a noncompetitive interaction mechanism (Brauns et al., 1997) . As illustrated in Fig. 2A) (Koschak et al., 2003; Hoda et al., 2005) . In comparison, membrane preparations from Ca v 1.2-transfected cells obtained in parallel experiments showed a robust signal with the expected binding densities (220 Ϯ 31 fmol/mg of protein; Fig. 2B ). Furthermore, specific binding could not be induced in the presence of 1, 3, and 10 M concentrations of the nonDHP Ca 2ϩ channel blockers (ϩ)-cis-diltiazem, (ϩ)-tetrandrine, and mibefradil (Table 1) , which caused a robust stimulation of (ϩ)-[ 3 H]isradipine binding to Ca v 1.2 (all three drugs) and Ca v 1.3 LTCCs [only tetrandrine and (ϩ)-cis-diltiazem; see legend to Table 1 ] expressed under identical experimental conditions. In summary, our data suggest that, contrary to other LTCCs, the expression of Ca v 1.4 channels cannot be quantified using radioreceptor assays, despite their sensitivity to LTCC modulators in electrophysiological studies (Koschak et al., 2003) . This could be due to a slightly higher K d (which would reduce occupancy below levels detectable under our experimental conditions) and/or to very fast binding kinetics that cause dissociation of labeled channel complexes during filter washes. Alignment of the amino acid residues critical for DHP interaction in Ca v 1.2 ␣ 1 subunits revealed that a tyrosine critical for DHP binding (present in Ca v 1.1, Ca v 1.2, and Ca v 1.3 ␣ 1 -subunits) is replaced by phenylalanine in Ca v 1.4 ␣ 1 (Phe1414). We therefore generated the Ca v 1.4 mutant F1414Y to test whether a tyrosine at this position could restore high affinity binding. The exchange did not yield measurable specific DHP binding (Fig. 2B) , despite efficient expression on the protein level ( Fig. 2A) . The failure of Ca v 1.4 detection by radioligand binding in our recombinant system implies that our DHP binding experiments with Ca v -DM membranes do not permit predictions about Ca v 1.4 expression in mouse brain.
Ca v 1.1 and Ca v 1.4 RNA Transcripts Are Expressed at Very Low Levels in Mouse Brain. Because Ca v 1.4 quantification by radioligand binding was not feasible, we used qPCR to determine the relative magnitude of Ca v 1.4 and Ca v 1.1 ␣ 1 transcript expression compared with Ca v 1.2 and Ca v 1.3 in both mouse and rat brain. In mouse, Ca v 1.2 was expressed at significantly (p Ͻ 0.001, n ϭ 9; one-way ANOVA, Bonferroni post-test) higher densities than Ca v 1.3 in whole-brain preparations and all brain regions investigated (Fig. 3) . Ca v 1.3 contributed 19.4 Ϯ 1.6% (mean, Ϯ S.E.M.) of total LTCC ␣ 1 -subunit transcripts in whole brain ( Fig. 3 ; 7595 median number of molecules/20-ng RNA equivalent), in accordance with our biochemical estimate. The relative abundance of Ca v 1.3 transcripts was higher in rat than in mouse brain, where Ca v 1.3 significantly exceeded Ca v 1.2 ␣ 1 RNA expression in all regions examined (Fig. 4) .
Ca v 1.4 comprised 0.03 Ϯ 0.01% of L-type transcripts in mouse whole brain, which corresponds to only 3 to 30 molecules/20-ng RNA equivalent. Although the Ca v 1.4 transcript number was within our quantification range (Ͼ10 molecules/20 ng; see Materials and Methods) in cerebral cortex and nucleus accumbens, the relative abundance and absolute N.S.B., no specific binding was observed in the absence or presence of the indicated concentrations of (Ϯ)-tetrandrine, (ϩ)-cis-diltiazem, and mibefradil in membrane preparations of two independent transfections. numbers were extremely low in these regions (cerebral cortex, 0.06 Ϯ 0.02%, 20-120 copies/20 ng; nucleus accumbens, 0.03 Ϯ 0.01%, 20-50 copies/20 ng).
Relative abundance (Ͻ 0.07%) and copy numbers (5-80, range in all brain regions) of Ca v 1.4 were similarly low in whole brain and all regions investigated in rat brain, where the assay was designed against a different region of the Ca v 1.4 gene (see Materials and Methods). However, up to 8600 copies/20 ng (rat) and 17,000 copies/20 ng (mouse) of Ca v 1.4 transcripts were detected in eye RNA preparations serving as positive controls (Figs. 3 and 4) . This confirmed that our assay was able to efficiently detect Ca v 1.4 ␣ 1 -subunit RNA.
Like for Ca v 1.4, the relative abundance of Ca v 1.1 transcripts was also very low in mouse brain (0.05 Ϯ 0.01% in whole brain), with the highest contribution in mouse cerebral cortex (0.12 Ϯ 0.05%). Relative Ca v 1.1 expression was higher in the rat with transcript numbers within our quantification range (i.e., 300 copies/20 ng) in cortex (500-2700 copies/20 ng, 2.39 Ϯ 0.36% of total LTCC ␣ 1 transcripts) and nucleus accumbens (390-760 copies/20 ng, 0.62 Ϯ 0.08%). As expected, Ca v 1.1 ␣ 1 RNA was heavily expressed in skeletal muscle preparations (up to 390,000 copies/20 ng in mouse and 860,000 copies/20 ng in rat), which served as positive controls (Figs. 3 and 4) .
It is noteworthy that the relative transcript abundance of -Brauns et al., 2004) . From the difference in binding density between Ca v 1.2DHP(Ϫ/Ϫ) and Ca v -DM mice, the contribution of Ca v 1.3 could be calculated as 10.7% of the total binding activity (see Fig. 1A ). Assuming that only Ca v 1.2 contributes to the remaining activity, 89.3% of binding in wildtype brains should be associated with Ca v 1.2; 4.4% of binding were retained in the Ca v -DM mice. If the latter represented lower affinity binding to the mutant Ca v 1.2 ␣ 1 subunit, it would correspond to a 20.3-fold decrease in occupancy. The higher K d (K d2 ) accounting for this decrease can be estimated as , amlodipine, and azidopine, but a 3-to 4-fold higher affinity was observed in WT brains for nifedipine and nitrendipine (Fig. 5, A and B ; Table 2 ; both the means of IC 50 values and the selectivity ratios were significantly different). This indicated that these compounds exhibit higher affinity for Ca v 1.2. To further confirm this finding, we repeated these experiments in membranes prepared from tsA201 cells transiently transfected with Ca v 1.2 and Ca v 1.3 ␣ 1 subunits (Fig. 5 , C and D; Table 3 ). Again, nitrendipine and nifedipine were 3-to 4-fold selective for Ca v 1.2. Selectivity (albeit weaker, 2-fold or less) of amlodipine, isradipine (selectivity ratio differences), and azidopine (mean IC 50 difference) was observed also in the recombinant system (Table 3 ). Our data demonstrate that some DHPs bind to LTCCs in an isoform-selective manner.
Discussion
Our data provide novel biochemical and pharmacological information about neuronal LTCCs in mammalian brain. (Koschak et al., 2001; Helton et al., 2005) .
We have previously obtained a higher estimate for the contribution of Ca v 1.3 channels to high affinity (ϩ)-[ 3 H]isradipine binding activity (20 -25%) using Ca v 1.3(Ϫ/Ϫ) mice (Clark et al., 2003) compared with the estimate obtained in this study. Although we found no evidence for changes of Ca v 1.2␣1 protein expression in Ca v 1.3(Ϫ/Ϫ) [and Ca v 1.2DHP(Ϫ/Ϫ)] mice in our previous analysis (Clark et al., 2003 , Sinnegger-Brauns et al., 2004 , we cannot rule out the possibility that a small decrease in Ca v 1.2␣1 protein expression resulted in an overestimation of Ca v 1.3 contribution in the knockouts. This again emphasizes the role of Ca v 1.2DHP(Ϫ/Ϫ) and Ca v -DM mice as alternative models to obtain more precise estimates for the relative abundance of the Ca v 1.3 channel protein in mouse brain.
Our finding of very low Ca v 1.1 and Ca v 1.4 RNA expression levels is strengthened by the fact that we obtained the same result in two different species. However, our data stand in contrast to a study reporting relatively high levels of Ca v 1.1 expression in various human brain regions (Takahashi et al., 2003) . In many of the brain regions investigated in that report, Ca v 1.1 transcript numbers were similar (such as in the putamen, occipital cortex, or spinal cord) or even exceeded those of Ca v 1.3, such as in the substantia nigra, pallidum, and caudate nucleus. We could not confirm such a high level of Ca v 1.1 expression in mouse and rat brain and different brain regions. In our study, the highest number of Ca v 1.1 transcripts was found in cerebral cortex and nucleus accumbens. In particular, we found no significant Ca v 1.1 expression in the caudate putamen of rat and mouse, the region reported to display the highest Ca v 1.1 expression level in human brain (Takahashi et al., 2003) , and Ca v 1.3 expression by far exceeded Ca v 1.1 levels in all brain areas tested in our experiments. It is also noteworthy that we have observed a greater relative abundance of Ca v 1.3 in rat brain compared with mouse. Whether these differences represent species diversity or can be attributed to other confounding factors such as age, gender, or strain polymorphisms remains to be determined. Given the potential role of Ca v 1.3 LTCC activity for age-induced decreases in cognitive function (Veng et al., 2003 , Herman et al., 1998 and the development of Parkinson disease (Chan et al., 2007) , our finding deserves more detailed analysis in further experiments.
We found that one of the most sensitive detection methods, reversible labeling with (ϩ)-[ 3 H]isradipine, failed to detect Ca v 1.4 LTCCs after expression in tsA201 cells under conditions that reliably yield Ca v 1.4 ␣ 1 protein in Western blots, give rise to Ca v 1.4-mediated currents (Koschak et al., 2003; Hoda et al., 2005) and allow robust detection of recombinant Ca v 1.2 and Ca v 1.3 LTCCs by this radioligand (Fig. 2, Tables  1 and 3 ). We show that this is not due to the phenylalanine substitution of a tyrosine in position 1414 in the Ca v 1.4 ␣ 1 subunit, a residue contributing to the DHP sensitivity of other LTCCs and present in all other LTCC ␣1 subunits. In Ca v 1.1 channels, replacement of the homologous tyrosine by a phenylalanine results in an about 3-fold increase in the K d for (ϩ)-[ 3 H]isradipine (Peterson et al., 1996) . Substituting Ca v 1.4 Phe1414 by tyrosine did not result in detectable bind- Ligand concentration was 0.13 to 0.15 nM. Membrane protein concentration was 40 to 100 g/ml. Data are given as means Ϯ S.D. for n ϭ 5. Statistical significance of selectivity was obtained as described in Table 2 . Selectivity ratios (WT:MUT) were calculated from individual experiments carried out in parallel for both channel isoforms. (Koschak et al., 2003) .
We demonstrated that nitrendipine and nifedipine exhibited 3-to 4-fold higher affinities for the Ca v 1.2 DHP binding pocket in the native membrane environment, a finding that was further confirmed employing recombinant channels. This represents the first comparison of the pharmacological properties of the DHP binding domains of native and recombinant Ca v 1.2 and Ca v 1.3 LTCC complexes. Nitrendipine and nifedipine are distinguished from the other DHPs tested by their NO 2 substituent at the 3Ј and 2Ј position of the phenyl ring, respectively. The existence of Ca v 1.2 selectivity was surprising given the very high sequence similarity within the DHP binding pocket of Ca v 1.2 and Ca v 1.3. Our findings indicate that nitrendipine and nifedipine can sense differences in the molecular architectures of these two binding domains. It therefore seems likely that such differences may also allow development of molecules with higher affinity for the Ca v 1.3 binding pocket. This could aid in the development of Ca v 1.3 selective LTCC blockers, which, based on emerging knowledge about the physiological role of Ca v 1.3 channels (Platzer et al., 2000; Striessnig et al., 2006; Chan et al., 2007) , could open novel therapeutic strategies for the treatment of depression and Parkinson disease.
